http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 04 Sep 2026 17:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27030593.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that <person>Sandesh Seth</person>, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual <span>Global Investment Conference</span>, being held <chron>September 14-16, 2026</chron>, in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>. Company management will also be available for one-on-one meetings with investors.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27030593.html Fri, 04 Sep 2026 17:05:00 -0400 ATNM http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27030593.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that <person>Sandesh Seth</person>, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual <span>Global Investment Conference</span>, being held <chron>September 14-16, 2026</chron>, in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>. Company management will also be available for one-on-one meetings with investors.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27030593.html Fri, 04 Sep 2026 17:05:00 -0400 ATNM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Shetty+Ajit/27030550.html si-local-file:///var/storage/secattach/20260904/27030550.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Shetty+Ajit/27030550.html Fri, 04 Sep 2026 17:01:00 -0400 ATNM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Almenoff+June+Sherie/27030556.html si-local-file:///var/storage/secattach/20260904/27030556.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Almenoff+June+Sherie/27030556.html Fri, 04 Sep 2026 17:01:00 -0400 ATNM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Nicholson%2C+C.+David/27030557.html si-local-file:///var/storage/secattach/20260904/27030557.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Nicholson%2C+C.+David/27030557.html Fri, 04 Sep 2026 17:01:00 -0400 ATNM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+SETH+SANDESH/27030558.html si-local-file:///var/storage/secattach/20260904/27030558.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+SETH+SANDESH/27030558.html Fri, 04 Sep 2026 17:01:00 -0400 ATNM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Chell+Jeffrey+W./27030538.html si-local-file:///var/storage/secattach/20260904/27030538.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Chell+Jeffrey+W./27030538.html Fri, 04 Sep 2026 17:00:00 -0400 ATNM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Steinhart+Richard+I/27030540.html si-local-file:///var/storage/secattach/20260904/27030540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Actinium+Pharmaceuticals++For%3A+Sep+02++Filed+by%3A+Steinhart+Richard+I/27030540.html Fri, 04 Sep 2026 17:00:00 -0400 ATNM http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html Fri, 14 Aug 2026 17:02:00 -0400 A.60001765 ATNM O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html Fri, 14 Aug 2026 17:02:00 -0400 A.60001765 ATNM O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html Fri, 14 Aug 2026 17:02:00 -0400 A.60001765 ATNM O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html Fri, 14 Aug 2026 17:02:00 -0400 A.60001765 ATNM O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html Fri, 14 Aug 2026 17:02:00 -0400 A.60001765 ATNM O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html Fri, 14 Aug 2026 17:02:00 -0400 A.60001765 ATNM O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html Fri, 14 Aug 2026 17:02:00 -0400 A.60001765 ATNM O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Actimab-A+Intellectual+Property+and+Manufacturing+Advances+and+Provides+NYSE+American+Listing+Update/26932446.html Fri, 14 Aug 2026 17:02:00 -0400 A.60001765 ATNM O.06705834 O.20738543 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Actinium+Pharmaceuticals++For%3A+Aug+12/26932437.html si-local-file:///var/storage/secattach/20260814/26932437.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Actinium+Pharmaceuticals++For%3A+Aug+12/26932437.html Fri, 14 Aug 2026 17:01:00 -0400 ATNM O.06705834 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Actinium+Pharmaceuticals++For%3A+Aug+12/26932437.html si-local-file:///var/storage/secattach/20260814/26932437.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Actinium+Pharmaceuticals++For%3A+Aug+12/26932437.html Fri, 14 Aug 2026 17:01:00 -0400 ATNM O.06705834 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Actinium+Pharmaceuticals++For%3A+Jun+30/26892023.html si-local-file:///var/storage/secattach/20260807/26892023.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Actinium+Pharmaceuticals++For%3A+Jun+30/26892023.html Fri, 07 Aug 2026 17:01:00 -0400 ATNM O.06705834 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Actinium+Pharmaceuticals++For%3A+Jun+30/26892023.html si-local-file:///var/storage/secattach/20260807/26892023.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Actinium+Pharmaceuticals++For%3A+Jun+30/26892023.html Fri, 07 Aug 2026 17:01:00 -0400 ATNM O.06705834 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Actinium+Pharmaceuticals++For%3A+Jun+18/26667071.html si-local-file:///var/storage/secattach/20260618/26667071.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Actinium+Pharmaceuticals++For%3A+Jun+18/26667071.html Thu, 18 Jun 2026 17:01:00 -0400 ATNM O.06705834 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Actinium+Pharmaceuticals++For%3A+Jun+18/26667071.html si-local-file:///var/storage/secattach/20260618/26667071.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Actinium+Pharmaceuticals++For%3A+Jun+18/26667071.html Thu, 18 Jun 2026 17:01:00 -0400 ATNM O.06705834 http://www.streetinsider.com/Corporate+News/Actinium+presents+ATNM-400+data+at+SNMMI+showing+activity+in+lung+cancer/26595732.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data on ATNM-400 for non-small cell lung cancer at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting on June 2.</p><p>The data showed ATNM-400 demonstrated activity in both KRAS and EGFR mutant lung cancer models. In KRAS-mutant studies, ATNM-400 outperformed standard treatments sotorasib and adagrasib when used alone. The standard treatments increased expression of ATNM-400's target by more than 3.5-fold and enhanced effectiveness when combined with ATNM-400.</p><p>In EGFR-mutant models, ATNM-400 combined with osimertinib resulted in complete tumor regression in treated animals. ATNM-400 achieved 75% tumor growth inhibition as a single http://www.streetinsider.com/Corporate+News/Actinium+presents+ATNM-400+data+at+SNMMI+showing+activity+in+lung+cancer/26595732.html Wed, 03 Jun 2026 08:02:57 -0400 ATNM http://www.streetinsider.com/FDA/Actinium+presents+ATNM-400+data+at+SNMMI+showing+activity+in+lung+cancer/26595732.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data on ATNM-400 for non-small cell lung cancer at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting on June 2.</p><p>The data showed ATNM-400 demonstrated activity in both KRAS and EGFR mutant lung cancer models. In KRAS-mutant studies, ATNM-400 outperformed standard treatments sotorasib and adagrasib when used alone. The standard treatments increased expression of ATNM-400's target by more than 3.5-fold and enhanced effectiveness when combined with ATNM-400.</p><p>In EGFR-mutant models, ATNM-400 combined with osimertinib resulted in complete tumor regression in treated animals. ATNM-400 achieved 75% tumor growth inhibition as a single http://www.streetinsider.com/FDA/Actinium+presents+ATNM-400+data+at+SNMMI+showing+activity+in+lung+cancer/26595732.html Wed, 03 Jun 2026 08:02:57 -0400 ATNM http://www.streetinsider.com/Press+Releases/Actinium+Presents+New+ATNM-400+Data+in+KRAS+and+EGFR+Mutant+Models+at+SNMMI+2026+Supporting+a+Mutation-Agnostic+Opportunity+In+Non-Small+Cell+Lung+Cancer/26595683.html <div class="xn-content"> <ul type="disc"><li>New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination<br /> </li><li>Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm<br /> </li><li>The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations<br http://www.streetinsider.com/Press+Releases/Actinium+Presents+New+ATNM-400+Data+in+KRAS+and+EGFR+Mutant+Models+at+SNMMI+2026+Supporting+a+Mutation-Agnostic+Opportunity+In+Non-Small+Cell+Lung+Cancer/26595683.html Wed, 03 Jun 2026 08:00:00 -0400 A.07197289 ATNM O.06705834 O.22039545